Yasunori Kaneko - 27 Feb 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
27 Feb 2025
Net transactions value
+$201,200
Form type
4
Filing time
27 Feb 2025, 19:06:05 UTC
Previous filing
07 Jun 2024
Next filing
12 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Purchase $201,200 +20,000 +238% $10.06 28,400 27 Feb 2025 Direct F1
holding RCUS Common Stock 252,524 27 Feb 2025 By Kaneko Investments, LLC
holding RCUS Common Stock 152,981 27 Feb 2025 By Trust F2
holding RCUS Common Stock 505,050 27 Feb 2025 By Kaneko Capital, LLC
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 Includes 6,800 shares of restricted stock units (previously reported) that vested on June 6, 2024 and were subsequently transferred to the reporting person's trust.